Updates are available Correction dated 2025-06-11
Click to view Correction: https://doi.org/10.1038/s44320-025-00126-0
-
Authors
Sommerauer, Christian https://orcid.org/0000-0001-7132-7172
Gallardo-Dodd, Carlos J
Savva, Christina
Hases, Linnea
Birgersson, Madeleine
Indukuri, Rajitha
Shen, Joanne X https://orcid.org/0009-0008-0322-5615
Carravilla, Pablo
Geng, Keyi
Nørskov Søndergaard, Jonas https://orcid.org/0000-0002-4438-6756
Ferrer-Aumatell, Clàudia
Mercier, Grégoire
Sezgin, Erdinc https://orcid.org/0000-0002-4915-388X
Korach-André, Marion
Petersson, Carl
Hagström, Hannes
Lauschke, Volker M https://orcid.org/0000-0002-1140-6204
Archer, Amena https://orcid.org/0000-0002-0400-4151
Williams, Cecilia
Kutter, Claudia https://orcid.org/0000-0002-8047-0058
-
Funding
Funding for this research was provided by:
Knut och Alice Wallenbergs Stiftelse (KAW 2016.0174)
Ruth och Richard Julins Stiftelse (2017-00358)
Ruth och Richard Julins Stiftelse (2018-00328)
Ruth och Richard Julins Stiftelse (2020-00294)
Ruth och Richard Julins Stiftelse (2022-00283)
Ruth och Richard Julins Stiftelse (2023-00162)
Ruth och Richard Julins Stiftelse (2021-00158)
Science for Life Laboratory (SFO_004)
Vetenskapsrådet (2019-05165)
Vetenskapsrådet (2019-01837)
Vetenskapsrådet (2021-02801)
Vetenskapsrådet (2022-00901)
Vetenskapsrådet (2023-02780)
Vetenskapsrådet (2023-02780)
Karolinska Institutet (2018-00904)
Karolinska Institutet (2021-00308)
Karolinska Institutet (2-3591/2014)
Karolinska Institutet (2018-00947)
Karolinska Institutet (2022-02535)
Karolinska Institutet (SRP_Diabetes_2023)
Robert Lundbergs Minnesstiftelse (2022-01158)
Robert Lundbergs Minnesstiftelse (2022-01159)
EC | Erasmus+ (20180716)
Novo Nordisk Fonden (NNF14OC0010705)
Lisa och Johan Grönbergs Stiftelse (2019-00173)
AstraZeneca (ICMC)
Lillian Sagen & Curt Ericsson research foundation (2021-00427)
Goesta Milton’s research foundation (2021-00527)
Chinese Scholarship Council (201700260271)
National Microscopy Infrastructure, NMI (VR-RFI 2016-00968)
National Academic Infrastructure for Supercomputing in Sweden (NAISS) at UPPMAX (storage: 2020/15-225,2021/23-691,2023/23-15; compute: 2020/16-291,2021/22-960,2023/22-36)
- License Information
-
More Information
Article History
Received: 14 September 2023
Revised: 10 February 2024
Accepted: 13 February 2024
First Online: 8 March 2024
Change Date: 11 June 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s44320-025-00126-0
Disclosure and competing interests statement
: CP is an employee of the Healthcare Business of Merck KGaA (Darmstadt, Germany). HH’s institutions have received research funding from Astra Zeneca, EchoSens, Gilead, Intercept, MSD, and Pfizer, all outside this study. HH has served as a consultant for Astra Zeneca and has been part of hepatic events adjudication committees for KOWA and GW Pharma. VML is a co-founder, CEO, and shareholder of HepaPredict AB. The remaining authors declare no competing interests.
